Swedish Orphan Biovitrum
kr 427.80Change from previous close: −1.52%Absolute change: −kr 6.60
At a glance
- Revenue growth
- +8.50%
- 2025 vs 2024
- Net income growth
- −87.70%
- 2025 vs 2024
- Net margin
- 1.7%
- 2024: 14.9%
Financial data
Amounts in millions of SEK; per-share values in SEK; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,912 | 1,126 | 2,981 | 1,840 | 1,448 | 2,295 | 1,797 | 1,201 | 2,329 | 2,256 | 1,072 | 1,058 |
| Depreciation and amortization | 804 | 782 | 685 | 903 | 889 | 938 | 842 | 924 | 915 | 909 | 793 | 936 |
| Capital expenditure | -10.0 | -3.0 | -5.0 | -8.0 | -20.0 | -7.0 | -12.0 | -21.0 | -27.0 | -109 | -700 | -102 |
| Investing cash flow | -378 | -8,746 | -1,077 | -2,699 | -424 | -94.0 | -101 | -2,202 | -44.0 | -745 | -458 | -414 |
| Financing cash flow | -1,419 | 7,502 | -1,899 | 857 | -988 | -2,293 | -1,150 | 860 | -2,042 | -1,865 | -358 | -774 |
| Debt issued | — | 7,347 | 3,055 | 802 | — | — | 14,220 | 698 | — | — | 24,506 | — |
| Debt repaid | -1,545 | -34.0 | -5,141 | -36.0 | -1,355 | -2,447 | -15,611 | -43.0 | -2,069 | -1,801 | -24,670 | -6,820 |
| Effect of exchange rates | 27.0 | 17.0 | -4.0 | -17.0 | 25.0 | -50.0 | -1.0 | -45.0 | 8.0 | -24.0 | -30.0 | 17.0 |
| Net change in cash | 142 | -101 | 2.0 | -19.0 | 61.0 | -143 | 546 | -185 | 252 | -377 | 226 | -112 |
| Free cash flow | 1,902 | 1,123 | 2,976 | 1,832 | 1,428 | 2,288 | 1,785 | 1,180 | 2,302 | 2,147 | 372 | 956 |
| Levered free cash flow | 169 | 1,286 | 2,855 | -902 | 945 | 2,382 | 2,900 | -3,506 | 2,512 | -108 | 611 | 2,927 |